What is MS Phase 2 Study ACT-128800?

Category: Others


See also: Clinical Trial

NCT01006265 is a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of 3 doses of ACT-128800 administered for 24 weeks in patients with relapsing-remitting multiple sclerosis. Other study name is AC-058B201.

Last updated:
There are no evaluations for MS Phase 2 Study ACT-128800.